Taiwan Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Taiwan Pharmaceuticals and Healthcare Report

Taiwan Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Taiwan Pharmaceuticals and Healthcare Report
Published Oct 08, 2016
91 pages — Published Oct 08, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

In June ----, Lin Tzou-yien, the Minister of Health and Welfare, noted that the authorities will negotiate with the pharmaceutical industry to find solutions to affordable new drugs. While steps taken to improve access to hepatitis C treatments are positive, there are concerns that this will limit the reimbursement of new treatments for other conditions. ...While steps taken to improve access to hepatitis C treatments are positive, there are concerns that this will limit the reimbursement of new treatments for other conditions. In August ----, the National Health Insurance Authority noted that a decision on whether new drugs for hepatitis C will be made available under the National Health Insurance Scheme will be concluded in October ----. A co-payment for these treatments has been proposed with local news sources reporting a range of ----- . ...This makes up part of the country s New Southbound Policy ; other markets that have also been identified include Bangladesh, India and Sri Lanka. As part of efforts to support exports to South East Asia, the government supported Taiwan External Trade Development organised a medical trade mission to Myanmar, Thailand and Singapore in July ----.

...A possible free trade agreement with the US threatens the supply of essential medicines to low-income sectors in the country. Overhaul of the National Health Insurance system to encourage more rational pharmaceutical spending. ...Removal of low-potency drugs and health supplements from reimbursement and reductions in reimbursement prices paid by the NHI to medical facilities. The government s plan to omit all brand-name products from the reimbursement list and to use only generic medicines instead is causing further friction. Relations with China face significant downside risk following the electoral win of the Democratic Progressive Party, with negative implications for Taiwan drugmakers invested in China. ...The government s plan to omit all brand-name products from the reimbursement list and to use only generic medicines instead is causing further friction. Relations with China face significant downside risk following the electoral win of the Democratic Progressive Party, with negative implications for Taiwan drugmakers invested in China.

...Relatively opaque regulatory environment favouring local industry over foreign firms. Tight-budgeted hospital market accounts for -- of total, which limits profits. ...

  
Source:
Document ID
1748-2232
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Taiwan Pharmaceuticals and Healthcare Report" Oct 08, 2016. Alacra Store. Dec 02, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Taiwan-Pharmaceuticals-and-Healthcare-Report-2026-122>
  
APA:
Business Monitor International - Industry Reports. (2016). Taiwan Pharmaceuticals and Healthcare Report Oct 08, 2016. New York, NY: Alacra Store. Retrieved Dec 02, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Taiwan-Pharmaceuticals-and-Healthcare-Report-2026-122>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.